Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Chronic Obstructive Lung Disease | Study protocol

Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial

Authors: Sheling Xie, Peng Yan, Chen Yao, Xiaoyan Yan, Yuliang Huo, Junhua Zhang, Si Liu, Zhiqiao Feng, Hongcai Shang, Lixin Xie

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the leading cause of mortality in chronic obstructive pulmonary disease (COPD). Traditional Chinese medicine (TCM) has been widely used in Asia as an adjunct treatment for AECOPD to improve the patients’ symptoms. Xuebijing (XBJ) injection is one of the major herbal medicines used in TCM. Previous small-sample clinical trials have proven its efficacy and safety in the treatment of AECOPD; however, the current data on XBJ as an adjunct therapy are insufficient. The present study will be a multi-center randomized clinical trial (RCT) to evaluate the efficacy and safety of XBJ injection in AECOPD and explore its influence on the immune function based on the altered levels of T cells.

Methods

This study will be a prospective, randomized, placebo-controlled, blinded, multi-center trial. A total of 300 eligible patients will be randomly assigned to the treatment or placebo control group in a 1:1 ratio using a central randomization system. The treatment group will receive routine medication plus XBJ injection, and the control group will receive routine medication plus 0.9% NaCl injection. The patients will receive the corresponding treatment for 5 days starting within 24 h of enrollment. The primary outcome, the of rate endotracheal intubation, will be evaluated on day 28 after treatment. The secondary outcomes will include changes in immune and inflammatory indicators, respiratory support, mortality rate after 28 days, blood gas analysis, improvement in Acute physiology and chronic health evaluation (APACHE) II scores and clinical symptoms, and the length and cost of intensive care unit stay and hospitalization. The safety of the interventions will be assessed throughout the trial.

Discussion

This is the first and largest randomized, controlled, blinded trial that evaluates the efficacy of XBJ injection as adjuvant therapy for AECOPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of the disease and identify the underlying mechanisms.

Trial registration

ClinicalTrials.gov, NCT02937974. Registered on 13 October 2016. Chinese clinical trial registry, ChiCTR-IPR-17011667. Registered on 15 June 2017.
Appendix
Available only for authorised users
Literature
1.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557–82.CrossRef
2.
Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139(4):920–9.CrossRef
3.
Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–60.CrossRef
4.
MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):530–5.CrossRef
5.
Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(2 Suppl):5S–9S.CrossRef
6.
Rubinsztajn R, Przybylowski T, Maskey-Warzechowska M, Karwat K, Chazan R. Exacerbations of chronic obstructive pulmonary disease and quality of life of patients. Adv Exp Med Biol. 2016;884:69–74.CrossRef
7.
Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–38.CrossRef
8.
Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.CrossRef
9.
Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–8.CrossRef
10.
Lima FV, Yen TY, Patel JK. Trends in in-hospital outcomes among adults hospitalized with exacerbation of chronic obstructive pulmonary disease. COPD. 2015;12(6):636–42.PubMed
11.
Shi L, Zhu B, Xu M, Wang X. Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics. Cell Biol Toxicol. 2018;34(2):109–123.
12.
Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445–54.CrossRef
13.
Afshar R, Medoff BD, Luster AD. Allergic asthma: a tale of many T cells. Clin Exp Allergy. 2008;38(12):1847–57.CrossRef
14.
Wang H, Ying H, Wang S, Gu X, Weng Y, Peng W, et al. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin Respir J. 2015;9(3):330–41.CrossRef
15.
Jin Y, Wan Y, Chen G, Chen L, Zhang MQ, Deng L, et al. Treg/IL-17 ratio and Treg differentiation in patients with COPD. PLoS One. 2014;9(10):e111044.CrossRef
16.
Xiong X, Jin Y, Zhou Q, Zhang X, Du W, Liu W, et al. Correlation between FoxP3 regulatory T cells and chronic obstructive pulmonary disease. Natl Med J China. 2008;88(7):471–4.
17.
Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD). 2016. Available from: http://​goldcopd.​org/​.
18.
Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–65.CrossRef
19.
Liu S, Chen J, He Y, Wu L, Lai J, Zuo J, et al. Comparative effectiveness of six Chinese herb formulas for acute exacerbation of chronic obstructive pulmonary disease: protocol for systematic review and network meta-analysis. BMJ Open. 2017;7(8):e17099.
20.
Liu M, Zhong X, Li Y, Zheng F, Wu R, Sun Y, et al. Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2014;14:239.CrossRef
21.
Jiansheng L, Haifeng W, Suyun L, Hailong Z, Xueqing Y, Xiaoyun Z, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med. 2016;29:109–15.CrossRef
22.
Duan L, Ning C. Observation curative effect of Xuebijing injection synergisticin treatment of acute exacerbation of chronic obstructive pulmonary disease. China Contin Med Educ. 2015;7(31):219–20.
23.
Peng Y, Mao Y, Zhu J, Chen H, Qiu X, Jiang J, et al. A clinical study of short-term Xuebijing injection on treatment of patients with acute exacerbation of chronic obstructive pulmonary disease. Chin J TCM WM Crit Care. 2008;03:178–80.
24.
Li X, Wang L, Zhang J, Li H, Liu Y. Effect of Xuebijing injection on T lymphocyte function in patients with chronic obstructive pulmonary disease. Chin J Emerg Med. 2007;12:1301–4.
25.
Dai X, Yao Y, Ai H. Effect of apoptosis of CD4+CD25+ regulatory T lymphocytes on polarization of helper T lymphocytes and potential interventional influence of Xuebijing injection in septic rats. Chin Crit Care Med. 2009;21(3):135–8.
26.
Gao Y, Chai Y, Yao Y. Advancement in the research of mechanism of immune dysfunction in sepsis and the regulatory effects of Xuebijing injection. Clin J Burns. 2013;29(2):162–5.
27.
Collaborative Research Group of Noninvasive Mechanical Ventilation for Chronic Obstructive Pulmonary Disease. Early use of noninvasive positive pressure ventilation for patients with acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial. Chin J Tuberc Respir Dis. 2005;28(10):20–4.
28.
Wang P, Song Y, Liu Z, Wang H, Zheng W, Liu S, et al. Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial. Trials. 2016;17(1):142.CrossRef
29.
Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7:D4104.
30.
Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006;19(4):637–57.CrossRef
31.
Waters B, Muscedere J. A 2015 update on ventilator-associated pneumonia: new insights on its prevention, diagnosis, and treatment. Curr Infect Dis Rep. 2015;17(8):496.CrossRef
32.
Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. 2004;350(24):2452–60.CrossRef
33.
Limsuwat C, Mankongpaisarnrung C, Dumrongmongcolgul N, Nugent K. Factors influencing the length of hospital stay in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to intensive care units. Qual Manag Health Care. 2014;23(2):86–93.CrossRef
34.
Sivapalan P, Moberg M, Eklof J, Janner J, Vestbo J, Laub RR, et al. A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - the CORTICO steroid reduction in COPD (CORTICO-COP) study protocol. BMC Pulm Med. 2017;17(1):114.CrossRef
35.
Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med. 2003;97 Suppl C:S51–9.CrossRef
36.
Sales DS, Ito JT, Zanchetta IA, Annoni R, Aun MV, Ferraz L, et al. Regulatory T-cell distribution within lung compartments in COPD. COPD. 2017;14(5):533–42.CrossRef
37.
Vargas-Rojas MI, Ramirez-Venegas A, Limon-Camacho L, Ochoa L, Hernandez-Zenteno R, Sansores RH. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med. 2011;105(11):1648–54.CrossRef
38.
Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930–6.CrossRef
39.
Li XJ, Zhang HY. Western healers in traditional Chinese medicine. EMBO Rep. 2008;9(2):112–3.CrossRef
40.
Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE. Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel. 2010;13(1):50–65.PubMed
41.
Song Y, Jiang W. Xuebijing injection in the treatment of sepsis with multiple organ dysfunction syndrome in 49 cases. Chin J Tradit Med Sci Technol. 2007;14:344.
42.
Huang H, Ji L, Song S, Wang J, Wei N, Jiang M, et al. Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS. Phytochem Anal. 2011;22(4):330–8.CrossRef
43.
Liu Y, Tian X, Cui M, Zhao S. Safflower yellow inhibits angiotensin II-induced adventitial fibroblast proliferation and migration. J Pharmacol Sci. 2014;126(2):107–14.CrossRef
44.
Navarrete S, Alarcón M, Palomo I. Aqueous extract of tomato (Solanum lycopersicum L.) and ferulic acid reduce the expression of TNF-α and IL-1β in LPS-activated macrophages. Molecules. 2015;20(8):15319–29.CrossRef
45.
Lu Y, Gu L, Huang W. Effect of Xuebijing injection on peripheral T-lymphocyte subpopulations in patients with severe trauma. Chin J Traumatol (Engl Ed). 2010;13(2):72–6.
Metadata
Title
Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial
Authors
Sheling Xie
Peng Yan
Chen Yao
Xiaoyan Yan
Yuliang Huo
Junhua Zhang
Si Liu
Zhiqiao Feng
Hongcai Shang
Lixin Xie
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3204-z

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Study protocol

The impact of lifestyle Physical Activity Counselling in IN-PATients with major depressive disorders on physical activity, cardiorespiratory fitness, depression, and cardiovascular health risk markers: study protocol for a randomized controlled trial

Research

An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units

Study protocol

Anesthetics to Prevent Lung Injury in Cardiac Surgery (APLICS): a protocol for a randomized controlled trial

Study protocol

GoPerio - impact of a personalized video and an automated two-way text-messaging system in oral hygiene motivation: study protocol for a randomized controlled trial

Study protocol

The trial to reduce antimicrobial use in nursing home residents with Alzheimer’s disease and other dementias: study protocol for a cluster randomized controlled trial

Study protocol

Medial malleolus: Operative Or Non-operative (MOON) trial protocol - a prospective randomised controlled trial of operative versus non-operative management of associated medial malleolus fractures in unstable fractures of the ankle